Literature DB >> 26181265

Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs.

Sham Mailankody1, Vinay Prasad1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26181265     DOI： 10.1001/jamaoncol.2015.0373

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  81 in total

1.  Ramucirumab for Colon Cancer and the Problem of Rising Prices Independent of Benefits.

Authors:  Peter B Bach
Journal:  Oncologist       Date:  2015-08-11

2.  The Value of Considering Cost, and the Cost of Not Considering Value.

Authors:  Leonard B Saltz
Journal:  J Clin Oncol       Date:  2015-12-14       Impact factor: 44.544

Review 3.  Cancer drug development: The missing links.

Authors:  Ajaikumar B Kunnumakkara; Devivasha Bordoloi; Bethsebie Lalduhsaki Sailo; Nand Kishor Roy; Krishan Kumar Thakur; Kishore Banik; Mehdi Shakibaei; Subash C Gupta; Bharat B Aggarwal
Journal:  Exp Biol Med (Maywood)       Date:  2019-04-08

4.  Total and out-of-pocket expenditures among women with metastatic breast cancer in low-deductible versus high-deductible health plans.

Authors:  Christine Leopold; Anita K Wagner; Fang Zhang; Christine Y Lu; Craig C Earle; Larissa Nekhlyudov; Dennis Ross-Degnan; J Frank Wharam
Journal:  Breast Cancer Res Treat       Date:  2018-06-01       Impact factor: 4.872

5.  Conditional approval of cancer drugs in Canada: accountability and impact on public funding.

Authors:  S K Andersen; N Penner; A Chambers; M E Trudeau; K K W Chan; M C Cheung
Journal:  Curr Oncol       Date:  2019-02-01       Impact factor: 3.677

6.  Variation of Cost among Anti-cancer Drugs Available in Indian Market.

Authors:  Bhanu Prakash Kolasani; Divyashanthi Chellathambi Malathi; Raghunatha Rao Ponnaluri
Journal:  J Clin Diagn Res       Date:  2016-11-01

Review 7.  Combining drugs and extending treatment - a PFS end point is not sufficient.

Authors:  Bishal Gyawali; Vinay Prasad
Journal:  Nat Rev Clin Oncol       Date:  2017-05-23       Impact factor: 66.675

8.  Financial Conflicts of Interest Among Oncologist Authors of Reports of Clinical Drug Trials.

Authors:  Cole Wayant; Erick Turner; Chase Meyer; Philip Sinnett; Matt Vassar
Journal:  JAMA Oncol       Date:  2018-10-01       Impact factor: 31.777

9.  Survival impact and toxicity of metformin in head and neck cancer: An analysis of the SEER-Medicare dataset.

Authors:  William A Stokes; Megan Eguchi; Arya Amini; Mohammad K Hararah; Ding Ding; Jessica D McDermott; Cathy J Bradley; Sana D Karam
Journal:  Oral Oncol       Date:  2018-06-30       Impact factor: 5.337

10.  Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma.

Authors:  Scott F Huntington; Gottfried von Keudell; Amy J Davidoff; Cary P Gross; Sapna A Prasad
Journal:  J Clin Oncol       Date:  2018-10-04       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.